Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.70 USD

38.70
1,363,791

-0.46 (-1.18%)

Updated Jul 15, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

by Zacks Equity Research

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

by Zacks Equity Research

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

by Zacks Equity Research

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

by Zacks Equity Research

Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.

Is Nuveen ESG International Developed Markets Equity ETF (NUDM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NUDM

The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca

by Zacks Equity Research

GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed

by Kinjel Shah

GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results

GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance

by Zacks Equity Research

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

by Zacks Equity Research

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

GSK Gears Up to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

by Zacks Equity Research

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $42.29 in the latest trading session, marking a +0.09% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

GSK Completes Demerger of Consumer Healthcare Business

by Zacks Equity Research

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

The Zacks Analyst Blog Highlights Apple, UnitedHealth Group, Equinor, GSK and Eaton

by Zacks Equity Research

Apple, UnitedHealth Group, Equinor, GSK and Eaton have been included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Apple, UnitedHealth, Equinor & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH), and Equinor ASA (EQNR).

GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $40.22 in the latest trading session, marking a -1.71% move from the prior day.

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

by Zacks Equity Research

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.

GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $40.92 in the latest trading session, marking a -1.25% move from the prior day.

GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $43.32, marking a +0.49% move from the previous day.

GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $43.30, marking a -1.03% move from the previous day.

GlaxoSmithKline (GSK) Stock Moves -0.8%: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.

Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA

by Zacks Equity Research

Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.

Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation

by Zacks Equity Research

Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.